| 货号 | 10009644-1mg |
| 描述 | The Raf kinases activate cellular pathways that lead to cell proliferation and can contribute to certain types of cancer.1 BAY 43-9006 is an inhibitor of Raf-1 and B-Raf (IC50 = 6 and 22 nM, respectively), as well as several receptor tyrosine kinases, including VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50 = 90, 15, 20, 57, and 58 nM, respectively).1,2 It poorly inhibits ERK1, MEK1, and several other kinases (IC50= >10 μM). Through these effects BAY 43-9006 inhibits tumor angiogenesis and induces tumor cell apoptosis, particularly in renal cell carcinoma and hepatocellular carcinoma.3,4,5,6 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Lyons, J.F.,Wilhelm, S.,Hibner, B., et al. Discovery of a novel Raf kinase inhibitor. Endocrine-Related Cancer 8(3), 219-225 (2001). 2.Wilhelm, S.M.,Carter, C., and Tang, L. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64(19), 7099-7109 (2004). 3.Strumberg, D.,Clark, J.W.,Awada, A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of Sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4), 426-437 (2007). 4.Liu, L.,Cao, Y.,Chen, C., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research 66(24), 11851-11858 (2006). 5.Sulkes, A. Novel multitargeted anticancer oral therapies: Sunitinib and sorafenib as a paradigm. Isr.Med.Assoc.J. 12(10), 628-632 (2010). 6.Bhargava, P., and Robinson, M.O. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr.Oncol.Rep. 13(2), 103-111 (2011). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 464.8 |
| 分子式 | C21H16ClF3N4O3 |
| CAS号 | 284461-73-0 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |